Background: Breast carcinoma is a cancer with the highest number in women, Luminal B is the highest number of all types of invasive breast carcinoma in the world. Invasive breast carcinoma of luminal B is breast carcinoma with hormone-receptor positive (estrogen-receptor and/or progesterone-receptor positive), and either HER2 positive or HER2 negative with high levels of Ki-67. Determining the aggressiveness factor in invasive breast carcinoma is very important. PD-L1 is a checkpoint in the cancer cell immunity cycle that affects the aggressiveness of tumour cells and CD133 is a cancerous stem cell marker that plays a role in proliferation, renewal and invasion of tumour cells. This study aims to determine the relationship of PD-L1 and CD133 expression with metastasis in the invasive breast carcinoma of Luminal B subtype. Methods: This study was an observational analytic study with a case control design to analyze 40 cases of invasive breast carcinoma Luminal B subtype, then divided into 2 groups, metastasis and nonmetastasis groups of 20 cases respectively. Then, all samples were performed by PD-L1 and CD133 immunohistochemistry staining, and then were associated with metastasis. All data were analyzed statistically, tested with a value of p < 0.05 from a significant level then processed with SPSS 24.0 for Windows.
Introduction
Breast cancer is the most common cancer in women in the world. Globocan had recorded at least 2.1 million of new cases in 2018. Based on data from RSHS information system, invasive breast carcinoma is 55.4% of all breast cancer cases diagnosed and occupying the highest prevalence of all types of invasive breast carcinoma in RSHS during 2017. 1, 2 Breast carcinoma is caused by several factors including genetic change factors, hormonal and environmental influences, genetic changes in luminal B subtype carcinoma involving several gen, so that routine molecular examination of ER, PR and HER2 is not enough, and additional molecular examination can be used as a determinant of cell aggressiveness. 3 Metastatic cancer is the leading cause of death in patients diagnosed with breast cancer and other malignant tumours. Lymph node status is used to identify the prognosis, tumour stage, and selection of treatment modalities. Patients without lymph node metastasis have a better prognosis, while patients with positive axillary lymph node status of more than 6 have a higher risk of being able to distant metastasis. The progressivity of metastatic lymphatic pathways involves proliferation of lymphatic vessels (lymphangiogenesis), lymphovascular invasion, and lymph node metastases step by step. 4, 5, 6 Programmed death ligand 1 (PD-L1, also known as CD274 and B7-H1) PD-L1 functions if there is an interaction with its receptor, programmed death 1 (PD-1, CD279), which is located on the cellsur face as a cell surface protein and expressed in T cells, B cells, and dendritic cells. The PD-1 bond in PD-L1 will trigger signal inhibition, and result in reduced effect or cell differentiation, imbalance between immune cell proliferation, T cell apoptosis, energy and saturation. 7, 8, 9 Wang, et al, revealed that PD-L1 can activate the growth and metastasis of cervical cancer by activating the ITGB4/SNAI1/SIRT3 pathway signal. Expressions integrated as part of a receptor group on the cell surface strongly correlate with metastasis in several types of cancer, then in the immune function of the checkpoint on PD-L1 as a result of bonding with its receptor, PD-1. A hypothesis that explains PD-L1 may bind directly to integrin receptors to activate intracellular signalling pathways such as the AKT/GSK3β pathway can increase the ability of cells to migrate and be invasive is obtained. 6, 10, 11, 12, 13, 14, 15, 16, 17 Matsubara, et al. Reported the results of his research that inhibiting Hedgehog and mTOR will reduce the growth of CD133 + tumour cells on the L3.6pl cell line.41. Severe hypoxia is often found in breast cancer, so the levels of HIF-1α and HIF-2α proteins with immunohistochemical examination will increase compared to the normal surrounding tissue. Breast cancer needs HIF-1α and HIF-2α for cell growth, and metastasis to lymph nodes and lungs, by inducing EMT breast cancer stem cells to make it easier for migration and invasion. [19] [20] [21] [22] [23] [24] This study aimed to perceive the correlation of PD-L1 and CD133 expression with metastasis in invasive breast carcinoma of Luminal B subtype.
Materials And Methods

Patients' Selection
This study used retrospective analytic observational method with case control study design. All data were analyzed using chi-square test with p value < 0 The recording of research data is paraffin block numbers, medical record numbers, age, and histopathology types. Data recording of research was also conducted on outpatient medical records and hospitalizations of invasive breast carcinoma patients. Based on the acquisition of these data, they will be grouped based on invasive breast carcinoma of luminal B subtype (HER2 + 3 and HER2 -) metastasis and non metastasis according to the inclusion criteria, then a review of hematoxylin eosin preparations and representative blocks was selected. All of these cases were collected by paraffin blocks, assessed for the integrity of the blocks. Representative paraffin blocks were made by two preparations. The first preparation made from immunohistochemistry PD-L1 and CD133 was then assessed using Olympus CX21 light microscope with 10x and 40x magnification to be performed on immunoexpression.
Immunohistochemistry Assessment and Evaluation
Immunohistochemical (IHC) staining using the labelled The assessment of PD-L1 and CD133 using a semi quantitative scoring system (histoscore) expression was carried out by looking at the intensity and distribution of immunohistochemical staining. Tumour cells that show positive PD-L1 and CD133 on cell membranes and/or cytoplasm staining were considered positive. The staining intensity was scored as 0 (negative), 1+ (weak), 2+ (moderate), and 3+ (strong). The percentage of positively stained cells were scored as 0 (negative), 1 (<20%), 2 (20-50%), 3 (50-80%), or 4 (>80%). Histoscore values are obtained by multiplying the intensity and distribution, then made into two categories. Low histoscore values = 0-4 and High = 6-12. Then, they were assessed using a light microscope Olympus CX21 with magnification 10x and 40x for a proper assessment of the expression by two specialists in anatomical pathology without seeing the clinical description of each sample.
Statistical Analysis
Statistical analysis for categorical data was tested by chisquare test if the Chi-Square requirements were met when fulfilled, then the Fisher Exact test was used for 2x2 
Results
Patients' Characteristics
The number of patients in this study who met the inclusion criteria were 40 invasive breast carcinoma of Luminal B subtype samples, consisting of 20 samples of the Metastatic group and 20 other samples included in the Non-Metastatic group. Table 1 describes the overall subject characteristics of study patients according to age and category, tumour size, grade, 
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PD-L1 and CD133 Immunohistochemical Expression
The immunohistochemical expression of PD-L1 and CD133 was evaluated (shown in Figure 1 and 2, respectively). PD-L1 was highly expressed in 29 of 40 cases (72,5%). There were 31 of 40cases (77,5%) showing high CD133 expression. 
PD-L1 Expression
From the results of statistical tests on the research group in table 3, information was obtained that P value = 0.013 in the PDL-1 Category variable was smaller than 0.05 (P value < 0.05) which meant that it was significant or statistically significant thus it could be explained that there were differences in the proportion of statistically significant between the PDL-1 Category variables in the Metastatic and Non-Metastatic groups. Based on the Odds Ratio, it can be concluded that the possibility of the risk of patients with PDL-1 expression in the high category for metastasis is 7.364 times higher compared to that of the patients with low Category of PDL-1 expression with confidence intervals of 1.337-40.548. 
Multivariate Analysis
Multivariate analysis below shows that the two variables between PD-L1 expression and CD133 expression are all related simultaneously to metastasis in invasive breast carcinoma of luminal B subtypes. The risk of the metastatic event will increases if both PD-L1 and CD133 increases simultaneously. 25 The results of this study is in accordance with the above theory. Average median age was 47.50 years old (< 50 years old), the highest number of age groups was < 50 years old, the tumour size with the highest numbers in both groups was 2-5 cm and this was also according to the research conducted by Lee, et al. which discovered that primary tumours less than 2 cm in size had a low prognosis for developing metastatic breast carcinoma. Tumour size of 2-5 cm and more than 5 cm were at a very high risk for metastasis. 26 Grade with the highest number in both metastatic and non-metastatic groups was grade 3, and the highest number of stages in both groups had the same stages, at stage 3B, this was in accordance with the statement of Zhihua Li, et al that patients of breast carcinoma Luminal B had an average age younger than 50 years old, had aggressive properties, tumour size greater than 2 cm and more than 5 cm, and had higher histopathological degrees (2 and 3), and had the ability for lymphovascular invasion.27, 28 Table 1 and 2 of this study provide results in accordance with the theory that is significant in differences between the frequency of HER2+3 with metastatic, P = 0.008, so HER2 is very important role in the pathogenesis in several types of human cancer. HER2 regulates cell growth, survival, and differentiation through signal transduction pathways and plays a role in cell proliferation and differentiation, as expressed by Igbal, N et al. HER2 with homo or heterodimerization produces autophosphorylation of tyrosine residues in the cytoplasmic domain of receptors and initiates various signalling pathways. especially mitogen-activated protein kinas e (MAPK), phosphatidylinositol-4,5-bisphosphate 3-kinase (PI3K), and protein kinase C (PKC) resulting in cell proliferation, survival, differentiation, angiogenesis, and invasion.29,30 Lindsey, et al suggested that HER2 amplification also correlated significantly with the degree of disease, axillary lymph node involvement, histology type, absence of estrogen and progesterone receptors. 30 Immunoediting is a maladaptive reciprocal process. Immune checkpoint of T cells involved in autoimmunity absorbers in the peripheral effector phase of T cell activation is PD-1 (CD279), which leads to immune tolerance of tumour cells expressing PD-L1 (B7-H1; CD274) and PD-L2 (B7-DC). Programmed death ligand 1 (PD-L1) is a 40-kDa transmembrane protein encoded by the CD274 gene located on chromosome 9. PD-L1 is found in several types of malignancies including breast carcinoma.28, 31 The metastatic group in this study showed an increase in the histological score of PD-L1 expression and showed a significant relation with metastasis statistically. The higher the expression of PD-L1, the higher the cell's ability to migrate and metastasis, so that the results are consistent with the theory of the role of PD-L1 on metastasis. The results of this study correspond to the research of Karnik, et al which has concluded that the relationship between the expression of PD-L1 with a parameter of clinicopathologic and aggressiveness including tumour size, the degree of histopathology, invasion of vessels, estrogen receptor, progesterone receptor, HER2, Ki67, types of molecular and triple negative status. 32 an evidence that PD-L1 expression increased in cancerous stem cells in at least two cancer cells, and could be a promising factor to consider immunotherapy based on PD1/PD-L1 to achieve effective and efficient treatment results. 38 The increasing number of Luminal B subtypes of invasive ductal carcinoma cases with a higher aggressiveness factor than invasive ductal breast carcinoma Luminal A subtype causes a high incidence of recurrence and resistance to chemotherapy, so that the morbidity and mortality will increase. An evidence based on the role of PD-L1 as an immune checkpoint and CD133 as a marker of stem cells of breast cancer to the process of metastasis of tumour cells of breast, has been shown to contribute significantly to the factor of aggressiveness of the tumour cells, so that PD-L1 is needed as one checkpoint of immunity marker, and also CD133 as breast cancer stem cell marker, so that it can be used as a target therapy and as a prognosis marker too. 
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